BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Up 153.2% in July

BiomX Inc. (NYSEAMERICAN:PHGE) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 481,974 shares, a growth of 153.2% from the July 15th total of 190,323 shares. Approximately 4.1% of the shares of the company are sold short. Based on an average trading volume of 1,706,839 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On BiomX

A hedge fund recently bought a new position in BiomX stock. Alyeska Investment Group L.P. purchased a new stake in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned 5.99% of BiomX at the end of the most recent reporting period. 40.57% of the stock is owned by institutional investors.

BiomX Stock Down 5.1%

Shares of NYSEAMERICAN PHGE opened at $0.15 on Friday. The firm’s 50-day moving average price is $0.32 and its 200-day moving average price is $2.35. BiomX has a 52-week low of $0.12 and a 52-week high of $12.29. The company has a market cap of $1.73 million, a PE ratio of -0.05 and a beta of 1.35.

BiomX (NYSEAMERICAN:PHGE) last released its quarterly earnings data on Wednesday, May 20th. The company reported $7.38 earnings per share for the quarter. As a group, equities research analysts anticipate that BiomX will post -5.85 EPS for the current fiscal year.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.